Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 13, Number 1—January 2007


Model for Assessing Human Papillomavirus Vaccination Strategies

Elamin H. Elbasha*Comments to Author , Erik J. Dasbach*, and Ralph P. Insinga*
Author affiliations: *Merck Research Laboratories, North Wales, Pennsylvania, USA;

Main Article

Table 1

Cost-effectiveness analysis of alternative HPV vaccination strategies*

Discounted total
No vaccination72,659,3022,698,711––––––
12-y-old girls74,042,9902,699,1781,383,6874672,964
12-y-old girls and boys78,707,8252,699,3274,664,835149Dominated
12-y-old girls plus 12- to 24-y-old females catch-up74,815,6672,699,343–3,892,159164,666
12-y-old girls and boys plus 12− to 24-y-old females catch-up79,746,3572,699,4614,930,69011841,803
12-y-old girls and boys plus 12− to 24-y-old females and males catch-up81,761,2102,699,5062,014,8534545,056

*Assumes cost of vaccination series is US $360 and duration of protection is lifelong. All costs are measured in 2005 US dollars, and costs and QALY are discounted at 3%. HPV, human papillomavirus; QALY, quality-adjusted life years.
†Compared with the preceding nondominated strategy. Strategy A is dominated if there is another strategy, B, that is more effective and less costly than strategy A.

Main Article